Clinical trial
Quality of Life and Adverse Effects in Epilepsy Patients (EPIKA)
NCT00302991 · UCB Pharma, Industry · Completed
Key facts
| NCT number | NCT00302991 |
|---|---|
| Title | Quality of Life and Adverse Effects in Epilepsy Patients (EPIKA) |
| Official title | Quality of Life and Adverse Effects in Epilepsy Patients According to Treatment Group (EPIKA) |
| Lead sponsor | UCB Pharma, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Epilepsy |
| Enrollment | 180 |
| Start date | Mar 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Mar 15, 2006 |
| Last update posted | Jan 30, 2008 |
| Countries | Spain |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: